azn201506266k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2015
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC - Change in ADS ratio
AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.
ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.
Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.
A C N Kemp
Company Secretary
26 June 2015
CONTACT
Citibank Shareholder Services
|
PO Box 43077
Providence
RI 02940-3077
US
|
Tel (toll free in the US): +1-888-697-8018
Tel (outside the US): +1-781-575-4555
|
Media Enquiries
|
Esra Erkal-Paler
|
+44 20 7604 8030 (UK/Global)
|
|
Jacob Lund
|
+46 8 553 260 20 (Sweden)
|
|
Michele Meixell
|
+ 1 302 885 6351 (US)
|
Investor Enquiries
|
UK
|
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 20 7604 8199
|
mob: +44 7818 524185
|
|
Eugenia Litz
|
Respiratory, Inflammation and Autoimmunity
|
+44 20 7604 8233
|
mob: +44 7884 735627
|
|
Nick Stone
|
Cardiovascular and
Metabolic Disease
|
+44 1763 263 994
|
mob: +44 7717 618834
|
|
Karl Hård
|
Oncology
|
+44 20 7604 8123
|
mob: +44 7789 654364
|
|
Craig Marks
|
Infection, Neuroscience and Gastrointestinal Disease
|
+44 20 7604 8591
|
mob: +44 7881 615764
|
|
Christer Gruvris
|
|
+44 20 7604 8126
|
mob: +44 7827 836825
|
|
US
|
|
|
|
|
Dial / Toll-Free
|
|
301-398-3251
|
866-381-7277
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 26 June 2015
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|